Spectrum Pharmaceuticals (NASDAQ:SPPI) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday. The brokerage currently has a $20.00 target price on the biotechnology company’s stock. Zacks Investment Research‘s target price indicates a potential upside of 12.11% from the....More>>>
New York State Common Retirement Fund raised its stake in shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 30.7% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 56,216 shares of the biotechnology company’s stock after purchasing an additional 13,219 shares during the period. New York State Common Retirement....More>>>
Welcome to another edition of “3 Things in Biotech You Should Learn Today,” a daily digest dedicated to helping you keep tabs on the fast-moving world of biotech and pharmaceutical research.
Let’s get started!
AstraZeneca whiplash continues with more durvalumab news
In a scrambling defense of disappointing MYSTIC results for its immune checkpoint inhibitor....More>>>
ImmunoGen (NASDAQ:IMGN) is a clinical stage biotech company that is focused on cancer therapeutics. It has developed an antibody-drug conjugate or “ADC” technology which is already being used in an approved and marketed product and is also being developed for use in a few other clinical stage candidates that are part of ImmunoGen’s current pipeline. The lead pipeline candidate....More>>>
Year to date shares of Clearside Biomedical (CLSD) have risen by 50%, having pulled back after at one point doubling due to positive phase 3 data reported in March.
While Bay Area Biotech Investor gave me a heads up on it at the beginning of 2018, unfortunately I failed to follow through and investigate further.
Figure 1: CLSD daily advanced chart (Source: Finviz)